secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viracta Therapeutics, Inc. (—)
CIK:        0001061027
Form:       8-K
Filed at:   2024-11-29T23:59:59+00:00
Accession:  0000950170-24-131919
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Viracta (VIRX) receives Nasdaq delisting notice; fails bid price and equity rules, plans appeal hearing
--------------------------------------------------------------------------------

- Nasdaq delisting notice dated Nov 26 for bid price non-compliance and equity deficiency; 180-day compliance period expired Nov 25.
- Company will appeal to Nasdaq Listing Qualifications Panel to request extension and present plan to regain compliance.
- Appeal stays delisting pending hearing; no guarantee of extension or favorable outcome.
- Company also failed Nasdaq's $2.5M stockholders' equity requirement, reported Nov 21, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061027/000095017024131919/0000950170-24-131919-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061027/000095017024131919/virx-20241126.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-131919

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer